NO20063373L - CD40-antistoff-formuleringer og fremgangsmater - Google Patents
CD40-antistoff-formuleringer og fremgangsmaterInfo
- Publication number
- NO20063373L NO20063373L NO20063373A NO20063373A NO20063373L NO 20063373 L NO20063373 L NO 20063373L NO 20063373 A NO20063373 A NO 20063373A NO 20063373 A NO20063373 A NO 20063373A NO 20063373 L NO20063373 L NO 20063373L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- patient
- antibody formulations
- administering
- tumor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Det beskrives en fremgangsmåte for behandling av tumor hos en pasient, omfattende administrering til pasienten av et CD40 agonist antistoff i henhold til en intermittent doseringsplan. Det beskrives videre en fremgangsmåte for behandling av tumor i en pasient omfattende administrering av en kombinasjon av et CD40 agonist antistoff og en DNA replikasjonsinhibitor. Det beskrives videre en formulering for bruk ved slik behandling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53163903P | 2003-12-22 | 2003-12-22 | |
PCT/IB2004/004103 WO2005063289A1 (en) | 2003-12-22 | 2004-12-09 | Cd40 antibody formulation and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20063373L true NO20063373L (no) | 2006-09-21 |
NO343797B1 NO343797B1 (no) | 2019-06-11 |
Family
ID=34738672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063373A NO343797B1 (no) | 2003-12-22 | 2006-07-20 | Flytende farmasøytisk formulering inneholdende CD40-antistoff og anvendelse av slike. |
Country Status (20)
Country | Link |
---|---|
US (4) | US20050136055A1 (no) |
EP (3) | EP2218461B1 (no) |
JP (3) | JP2007515469A (no) |
KR (2) | KR100847944B1 (no) |
CN (2) | CN1897971A (no) |
AU (1) | AU2004308749B2 (no) |
BR (1) | BRPI0418029B8 (no) |
CA (2) | CA2704300A1 (no) |
DK (1) | DK2218461T3 (no) |
ES (1) | ES2580002T3 (no) |
HU (1) | HUE027717T2 (no) |
IL (2) | IL175540A (no) |
NO (1) | NO343797B1 (no) |
NZ (2) | NZ547162A (no) |
PL (1) | PL2218461T3 (no) |
RU (1) | RU2355421C2 (no) |
SI (1) | SI2218461T1 (no) |
TW (1) | TWI359671B (no) |
WO (1) | WO2005063289A1 (no) |
ZA (1) | ZA200603804B (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
KR20080079301A (ko) * | 2005-12-09 | 2008-08-29 | 시애틀 지네틱스, 인크. | Cd40 결합제를 이용하는 방법 |
EP2589654A1 (en) | 2006-05-03 | 2013-05-08 | The Regents of the University of Colorado, a body corporate | CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
US20090074711A1 (en) * | 2006-09-07 | 2009-03-19 | University Of Southhampton | Human therapies using chimeric agonistic anti-human cd40 antibody |
DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
WO2010024676A1 (en) * | 2008-08-29 | 2010-03-04 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Delivery of a cd40 agonist to a tumor draining lymph node of a subject |
US9561214B2 (en) * | 2008-10-16 | 2017-02-07 | Array Biopharma Inc. | Method of treatment using inhibitors of mitosis |
WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
WO2012123269A1 (en) | 2011-03-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Immunogenic compositions and methods for their use |
EP2505640A1 (en) | 2011-03-29 | 2012-10-03 | Neo Virnatech, S.L. | Vaccine compositions for birnavirus-borne diseases |
SG194701A1 (en) | 2011-04-29 | 2013-12-30 | Apexigen Inc | Anti-cd40 antibodies and methods of use |
EP3563865A3 (en) | 2012-05-04 | 2019-12-04 | Pfizer Inc | Prostate-associated antigens and vaccine-based immunotherapy regimens |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
ES2879552T3 (es) | 2012-10-30 | 2021-11-22 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
EP4269441A3 (en) | 2013-08-08 | 2024-01-24 | Cytune Pharma | Il-15 and il-15ralpha sushi domain based on modulokines |
PL3212230T3 (pl) | 2014-10-29 | 2021-07-26 | Seagen Inc. | Dawkowanie i podawanie niefukozylowanych przeciwciał anty-CD40 |
KR20210089270A (ko) | 2015-07-16 | 2021-07-15 | 바이오카인 테라퓨틱스 리미티드 | 암 치료용 조성물 및 방법 |
JP7208492B2 (ja) | 2016-03-10 | 2023-01-19 | シージー オンコロジー, インコーポレイテッド | 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法 |
CA3026880A1 (en) | 2016-06-08 | 2017-12-14 | Paul Foster | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
KR102019033B1 (ko) | 2016-11-11 | 2019-09-06 | 다이노나(주) | Cd40에 특이적으로 결합하는 항체 및 그의 용도 |
WO2018162450A1 (en) | 2017-03-06 | 2018-09-13 | Fundación Para La Investigación Médica Aplicada | New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells |
US11242397B2 (en) | 2017-06-01 | 2022-02-08 | Pb Immune Therapeutics Inc. | Anti-CD40 antibody and methods for blocking CD40-CD40L signaling |
EP3418302A1 (en) * | 2017-06-19 | 2018-12-26 | F. Hoffmann-La Roche AG | Administration routes for immune agonists |
WO2018220100A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Administration routes for immune agonists |
JP2021521804A (ja) | 2018-04-20 | 2021-08-30 | リビジェン バイオファーマ カンパニー リミテッド | 抗cd40抗体およびその使用 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN116178544A (zh) * | 2018-09-28 | 2023-05-30 | 礼进生物医药科技(上海)有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
KR20210097750A (ko) * | 2018-11-30 | 2021-08-09 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Cd40 항체 약학 조성물 및 이의 용도 |
EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
JP2023509359A (ja) | 2019-12-17 | 2023-03-08 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | 鉄依存性細胞分解の誘導物質との併用抗癌療法 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Name of the invention: antibody conjugates against ASGR1 and their uses |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
AU2022303363A1 (en) | 2021-06-29 | 2024-01-18 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5247069A (en) * | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
JP2547556B2 (ja) * | 1987-02-06 | 1996-10-23 | 株式会社 ミドリ十字 | r−グロブリンの液状製剤 |
SE8701004D0 (sv) | 1987-03-11 | 1987-03-11 | Astra Ab | Method for therapy of leukemias and certain other malignancies |
JPH03204821A (ja) * | 1989-12-28 | 1991-09-06 | Green Cross Corp:The | モノクローナル抗体含有水溶液の加熱処理方法 |
IL104684A0 (en) * | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
AU5098493A (en) | 1992-08-21 | 1994-03-15 | Schering Corporation | Cd40 ligand, anti cd40 antibodies, and soluble cd40 |
DE69433406T2 (de) * | 1993-10-01 | 2004-10-07 | Immunex Corp | Antikörper gegen cd40 |
NZ278740A (en) * | 1993-12-23 | 1998-05-27 | Immunex Corp | Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein |
GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
ES2190087T3 (es) * | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
WO2000072881A1 (en) * | 1999-06-01 | 2000-12-07 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
JP4516711B2 (ja) * | 1999-12-28 | 2010-08-04 | 中外製薬株式会社 | 安定な抗体組成物及び注射製剤 |
US6358670B1 (en) * | 1999-12-28 | 2002-03-19 | Electron Vision Corporation | Enhancement of photoresist plasma etch resistance via electron beam surface cure |
CN100490895C (zh) | 2000-02-01 | 2009-05-27 | 泛遗传学公司 | 结合cd40的apc激活分子 |
US6896885B2 (en) * | 2000-03-31 | 2005-05-24 | Biogen Idec Inc. | Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
US6838250B2 (en) | 2000-03-31 | 2005-01-04 | Ortho-Clinical Diagnostics, Inc. | Immunoassay for C-reactive protein |
US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
US7063845B2 (en) * | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
WO2002028480A2 (en) * | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies |
DK1324776T4 (en) * | 2000-10-12 | 2018-05-28 | Genentech Inc | CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
ATE556591T1 (de) * | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2002357060A1 (en) * | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
US20080009439A1 (en) * | 2002-11-05 | 2008-01-10 | Alsobrook John P | Compositions and Methods of Use for a Fibroblast Growth Factor |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
-
2004
- 2004-12-02 US US11/001,980 patent/US20050136055A1/en not_active Abandoned
- 2004-12-09 SI SI200432321A patent/SI2218461T1/sl unknown
- 2004-12-09 KR KR1020067012364A patent/KR100847944B1/ko active IP Right Grant
- 2004-12-09 JP JP2006546357A patent/JP2007515469A/ja active Pending
- 2004-12-09 CN CNA2004800385418A patent/CN1897971A/zh active Pending
- 2004-12-09 KR KR1020087004912A patent/KR20080023766A/ko not_active Application Discontinuation
- 2004-12-09 WO PCT/IB2004/004103 patent/WO2005063289A1/en active Application Filing
- 2004-12-09 EP EP10162787.5A patent/EP2218461B1/en active Active
- 2004-12-09 NZ NZ547162A patent/NZ547162A/en not_active IP Right Cessation
- 2004-12-09 NZ NZ583179A patent/NZ583179A/en not_active IP Right Cessation
- 2004-12-09 EP EP04801378A patent/EP1706143A1/en not_active Ceased
- 2004-12-09 HU HUE10162787A patent/HUE027717T2/en unknown
- 2004-12-09 RU RU2006120950/14A patent/RU2355421C2/ru active
- 2004-12-09 AU AU2004308749A patent/AU2004308749B2/en not_active Ceased
- 2004-12-09 CN CN2012100028652A patent/CN102552905A/zh active Pending
- 2004-12-09 PL PL10162787.5T patent/PL2218461T3/pl unknown
- 2004-12-09 CA CA2704300A patent/CA2704300A1/en not_active Abandoned
- 2004-12-09 CA CA2549652A patent/CA2549652C/en active Active
- 2004-12-09 BR BRPI0418029A patent/BRPI0418029B8/pt not_active IP Right Cessation
- 2004-12-09 EP EP16164228.5A patent/EP3081933A1/en not_active Withdrawn
- 2004-12-09 ES ES10162787.5T patent/ES2580002T3/es active Active
- 2004-12-09 DK DK10162787.5T patent/DK2218461T3/en active
- 2004-12-21 TW TW093139794A patent/TWI359671B/zh not_active IP Right Cessation
-
2006
- 2006-05-10 IL IL175540A patent/IL175540A/en active IP Right Grant
- 2006-05-12 ZA ZA200603804A patent/ZA200603804B/en unknown
- 2006-07-20 NO NO20063373A patent/NO343797B1/no not_active IP Right Cessation
-
2009
- 2009-07-14 US US12/502,587 patent/US20090311254A1/en not_active Abandoned
- 2009-10-11 IL IL201409A patent/IL201409A0/en unknown
-
2010
- 2010-12-23 US US12/978,272 patent/US20110104182A1/en not_active Abandoned
-
2011
- 2011-04-28 JP JP2011100868A patent/JP5634321B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-19 US US13/424,260 patent/US20120263732A1/en not_active Abandoned
-
2014
- 2014-06-12 JP JP2014121342A patent/JP2014205692A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063373L (no) | CD40-antistoff-formuleringer og fremgangsmater | |
ATE312635T1 (de) | Ventilanordnung | |
NO20026171L (no) | Topiske farmasöytiske formuleringer og fremgangsmåter for behandling | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
ATE405564T1 (de) | 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten | |
BR0205722A (pt) | Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor | |
GEP20053511B (en) | ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase | |
NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
HUP0401867A2 (hu) | A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére | |
BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
CY1107352T1 (el) | Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου | |
NO20101070L (no) | Fremgangsmate til dosering av et medikament, samt doseringsform | |
HK1080733A1 (en) | Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol | |
DK1397681T3 (da) | Fremgangsmåde til identificering af midler til behandling af diabetes | |
ATE350032T1 (de) | Verwendung der protein-kinase-c-epsilon- inhibitoren zur behandlung von schmerzen | |
DK1343472T3 (da) | Thixotropisk næsespray | |
DK1237562T3 (da) | Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme | |
NO20052313L (no) | Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av | |
SE0102887D0 (sv) | New formulation | |
EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
DE602004029993D1 (de) | Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit | |
ATE407925T1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
DE60122781D1 (de) | Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen | |
WO2004035030A3 (en) | Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain | |
ATE338560T1 (de) | Pharmazeutische zusammentsetzung zur medizinischen behandlung von gutartiger prostathyperplasie, dessen vorbereitungsmethode und dessen therapeutische verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |